Dull Q4FY17 could be a blessing in disguise
According to a report from CARE Ratings on the corporate performance of Q4FY17, the pharmaceuticals and drugs sector in India,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Editor’s note
Towards sustainability
Sustainability measures achieve the twin benefits of reducing operating costs while simultaneously meeting environmental goals
Bridging the skills gap
Beleaguered by warning letters and import recalls, pharmaceutical companies in India seem to be finally investing in upskilling…
Passing the buck?
Prime Minister Modi’s announcement that his government would ensure doctors prescribed generic medicines stirred a hornet’s nest
Does IP build or block?
Its been 17 years since the World Intellectual Property Organisation (WIPO) started marking April 26 as World Intellectual…
US-India relationship: Can it trump the odds?
Affordable and efficient healthcare systems is listed out as an area chosen for “Growing Convergence, Collaboration &…
Collaborate to conquer
Two rulings in the space of as many days demonstrate the fine balance required of India’s legal system when it comes to the…
Evolving an ‘India First’ policy
The countdown to the USTR for 2017 Special 301 Review has begun
Beyond the budget
The hype around the Union Budget 2017-18, especially after Prime Minister Modi's December 31 address was high but the general…
Pharma PSUs: Missed opportunity?
The turnover of the Indian pharmaceutical industry was estimated at Rs 2,04,627.1 crores in FY2015-16, registering a growth of 29…
Giving with a purpose
‘He who has health, has hope; and he who has hope, has everything,’ said Thomas Carlyle, social commentator and philosopher
More pain before the gain
An ICRA quarter update on the pharmaceutical sector does not have very encouraging news for 2017
Girding up for a VUCA world
The term VUCA, an acronym for volatility, uncertainty, complexity and ambiguity, was reportedly first coined by the US Army War…
More power to GST
The ongoing winter session of Parliament is crucial as there are many big ticket bills awaiting a nod
India Pharma Inc’s Trump card
Donald J Trump has beaten all odds to win the US election, much like the Indian pharmaceutical industry’s hard won rise as the…
In search of sustainable growth
When Ministers speak like CEOs, industry sits up and listens. The relatively newly minted state of Telangana is racing to catch up…
Abiding by the rules
The debate about replacing PET packaging with glass as packaging material for pharmaceuticals is reaching yet another milestone as…
Opportunities amidst challenges
MSF’s seven-year-old appeal campaign to reduce flu vaccine prices has finally borne fruit
Reviving APIs
Even as Indian pharmaceutical companies pursue aggressive plans for global expansion, there are deep challenges in the domestic…
Thriving through change
A recently released analysis of the global courier industry from
2010-2021, shows that the pharmaceutical sector accounts for just…